Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TP-05 in Healthy Participants at High Risk of Tick Exposure
NCT07562087Phase 2Active, not recruiting
- Sponsor
- Tarsus Pharmaceuticals, Inc.
- Start
- Mar 2026
- Primary completion
- Oct 2027
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lotilaner in Lyme disease (3 arms), sponsored by Tarsus Pharmaceuticals, Inc. Primary endpoints: Incidence of Treatment Emergent Adverse Events at 15 months, Clinically Significant Changes From Baseline Chemistry Laboratory Tests at 15 months and 5 more. Started Mar 2026; status: active, not recruiting.
02
Drugs
lotilaner
03
Conditions
Lyme disease
Beyond the preview
Go deeper on NCT07562087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07562087.